Table 1.

Issues to be discussed in head and neck MTB.

Tumor types	Treatment setting	Topics
SCCHN, resectable	Curative setting	Choice of upfront surgery or non-surgical treatment
LASCCHN	Definitive RT or CRT	Radiation dose, fraction, field Alternatives to definitive CRT regimen in CDDP-ineligible patients
LASCCHN, high-risk stage II laryngeal cancer	Definitive RT or CRT	Choice of RT alone or CRT
LASCCHN	ICT	Indication and purpose of ICT Alternatives to the ICT-TPF regimen
LASCCHN	Post-definitive RT/CRT	Diagnosis of post-definitive RT/CRT and its management Indication for salvage surgery
LASCCHN, oral cancer	Neoadjuvant chemotherapy	Indication and purpose of neoadjuvant chemotherapy
LASCCHN, pharyngeal/laryngeal/oral cancer, and others	Surgery and reconstruction	Surgical technique—such as setting the resection margin and reconstruction
LASCCHN, nasal and paranasal sinus cancer	Skull base surgery	Surgical technique, operation workflow
Postoperative high-risk SCCHN	Postoperative CRT	Choice of RT alone or CRT Alternatives to postoperative CRT regimen in CDDP-ineligible patients
Recurrent or metastatic disease	Palliative pharmacotherapy	Indication for pharmacotherapy Treatment regimen Indication for CGP test in rare cancer
	Palliative RT	Indication for re-irradiation Indication for stereotactic radiosurgery
Unresectable thyroid cancers	Palliative pharmacotherapy	Indication and timing of initiation of TKIs Indication for CGP test
All	Definitive and palliative setting	Symptomatic management Nutritional management Management for acute and late treatment-related toxicities Functional assessment Psychological and socioeconomic issues

SCCHN, squamous cell carcinoma of the head and neck; LA, locally advanced; RT, radiotherapy; CRT, chemoradiotherapy; CDDP, cisplatin; ICT, induction chemotherapy; TPF, Docetaxel plus CDDP and 5-fluorouracil; CGP, comprehensive cancer genomic profiling; TKI, tyrosine kinase inhibitor.